Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-2200

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71335-2200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

A line graph depicting the percentage of subjects achieving systolic blood pressure (SBP) below 140 mmHg against baseline SBP values ranging from 140 to 180 mmHg. Four lines represent different treatments: valsartan-HCTZ 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo, showing comparative efficacy in lowering SBP.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph comparing the percentage of patients with diastolic blood pressure (DBP) below 90 mmHg at baseline DBP values from 90 to 110 mmHg. It includes four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, each represented by distinct markers. The graph shows higher percentages for the combination versus individual components and placebo.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

A line graph showing the percentage of patients with systolic blood pressure (SBP) under 130 mmHg, plotted against baseline SBP values ranging from 140 to 180 mmHg. The graph compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, with Valsartan-HCTZ 320/25 mg showing the highest percentage of patients achieving SBP <130 mmHg across baseline SBP values.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line chart comparing the percentage of patients with diastolic blood pressure below 80 mmHg (% DBP <80) against baseline diastolic blood pressure (DBP) in mmHg. Four data series are shown: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The graph illustrates response trends for these treatments across baseline DBP values ranging from 90 to 110 mmHg.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure of valsartan, one of the active ingredients in the prescription drug combination valsartan and hydrochlorothiazide.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure diagram of the active ingredient hydrochlorothiazide in the drug product Valsartan and Hydrochlorothiazide.*

FDA Label Image

Label (Lbl713352200)

Label for Valsartan Hctz 320/25mg tablet, a film-coated oral tablet. The label notes packaging by Bryant Ranch Prepack in Burbank, CA, with reference to a similar product Diovan Hctz 320/25mg by Zhejiang Huahai Pharma Co., Ltd. The label includes storage instructions (20°-25°C) and cautions to keep out of reach of children. A barcode and NDC 71335-2201 are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.